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The results of many efforts to induce resistance in Macacus  rhesus 
monkeys against experimental poliomyelitis by means of inoculations 
of virus in one form or another have been summarized by Stewart 
and R_hoads (1929) (1) and in the volume published by the Milbank 
International  Committee  (1932) (2).  What  may  be  derived from 
these experiments, beginning with the first, undertaken 25 years ago 
by Flexner and Lewis (3), is that "it is impossible to protect monkeys 
by the use of killed virus and second, that a definite though inconstant 
resistance to poliomyelitis can be brought about by the intradermal 
and subcutaneous introduction of the living virus" (1).  The fact also 
emerges from the numerous trials hitherto reported that resistance is 
acquired by monkeys when a sufficient amount of active virus is given 
intra-  or  subcutaneously  in  one  massive  dose  (3,  4)or in smaller 
amounts repeated over a considerable period of time (3-6).  Even then 
protection is not afforded to some animals and the degree of immunity 
induced varies in others, while now and again a treated monkey suc- 
cumbs to the disease as a result of the inoculations (1,  5-8). 
Two noteworthy series of articles have recently appeared, in one of 
which was described the immunity obtained through the use of virus 
completely inactivated by 0.1 per cent formalin (Brodie, 9) and in the 
other the protection conferred  with active but ricinoleated  virus (Kolmer 
and his associates, 10).  While the principles underlying both methods 
had already been employed (2), the recent investigators report results 
which lead them to believe that immunity can be safely induced with 
their materials. 
Since on the basis of Brodie's and Kolmer's work widespread inocu- 
lations of children against poliomyelitis have been undertaken recently, 
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it was deemed desirable to restudy this problem, following as closely 
as possible the methods of these investigators.  The intention was to 
determine  whether  any advance has  been made  in  the  experimental 
immunization of monkeys over that which  has been accomplished in 
the past 25 years, and whether any procedure has been disclosed that 
might be practical for immunization of man. 
For  the  purpose  of  comparison  we  also  studied  another  form  of 
chemically treated  virus as immunizing  agent,  namely,  that precipi- 
tated by tannin, which will be described first. 
Methods 
Virus.--The animals selected as source of poliomyelitis virus were extensively 
paralyzed and  moribund  as  a  result  of  the  experimental  disease.  They were 
killed by ether inhalation and the spinal cord removed under aseptic conditions. 
The identification of the particular virus used in the preparation of each immu- 
nizing agent was ascertained by (a) animal inoculation with production of specific 
clinical  signs  and  pathological changes,  and by  (b)  neutralization  with  specific 
homologous strain antiserum.  The M.V. and Philadelphia strains  (11) of virus 
were employed. 
Method of Testing for  Acquired Active Immunity.--Monkeys  were tested for 
induced resistance by the inoculation of homologous strains intracerebrally and 
intranasally. 
The intracerebral test dose  1 consisted of 0.2 cc. of 5 per cent fresh poliomyelitis 
cord suspension which  was filtered through a  Berkefeld N  filter.  Kolmer (10), 
working with  the  M.V.  strain,  states that  one infective unit  was contained in 
0.05  cc.  of an unfiltered suspension  in some instances and  in 0.2  cc. in others. 
However this  may be,  the high  cost of monkeys makes it  impractical to  titrate 
each individual virus sample; hence the test dose for induced resistance should be 
one  that  experience has  shown  to  be  unequivocally effective.  The  dosage  as 
given in the following experiments has been consisfently employed in this labora- 
tory  for  many years  with  satisfactory results.  Normal  monkeys receiving it 
react with the experimental disease within,  as a  rule, 5 to 11 days; only excep- 
tionally does an animal resist.  All  the controls of the following  series  of tests 
developed the characteristic infection. 
The intranasal test for induced immunity consisted of the instillation into each 
nasal cavity of 1 cc. of 10 per cent glycerolated cord suspension,  and after 1 or 2 
days' interval the treatment was repeated.  The reaction was measured not only 
by clinical signs but also by cell counts of the spinal fluid withdrawn daily through 
cisternal puncture.  The method is essentially that of Flexner (12) and his asso- 
ciates and suffices satisfactorily to determine the state of immunity in a  treated 
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animal.  It may be said that the amount as given is not too drastic since in a col- 
lateral series of twenty-four monkeys,  twenty-one  developed  poliomyelitis;  the 
three unaffected ones could not be considered immune, only uninfluenced by the 
treatment, since one of them--the only one retested--was later shown to be sus- 
ceptible to a similar intranasal  instillation  of virus.  Hence the test dose as prac- 
tised is in the range of minimal infective dosage.  It is of interest  that all controls 
so treated which were employed  in the experiments  to be reported were success- 
fully infected. 
Test for Antiviral Bodies in Serum.--0.8  cc. of undiluted serum  is mixed with 
0.2 cc. of 5 per cent filtered fresh cord virus,  kept at 37°C. for 2 hours and in the 
cold for 16 to 18 hours, and then injected into the brain of monkeys.  For control, 
the serum is replaced by physiological saline solution.  Here again neutralization 
tests are carried out with the homologous strain of virus.  The test can be regarded 
as a practical one even though the precise titration of antibody content of a serum 
is not ascertained. 
Tannin-Precipitated  Virus as Immunizing Agent 
In a  correlated study on the virus of equine encephalomyelitis, it 
was found that vegetable-derlved tannin (tannic acid) precipitated the 
proteins of the tissue containing the virus and the latter precipitated 
with  the  proteins  remained  infective  although somewhat reduced  in 
potency (13).  The virus could not be designated as "attenuated" but 
merely  as  present  in  lesser  amounts  in  the  flocculated  substance. 
Under  these  conditions  the  infective  agent  retained  its  activity  for 
several  weeks.  As the  following will  show,  similar  results  were  ob- 
tained with tannin precipitates of active poliomyelitis tissues. 
Preparation of Immunizing  Agent.--2.5  gm.  of poliomyelitis  cord were thor- 
oughly ground with sand and suspended  during the grinding in 50 cc. of distilled 
water.  The  suspension  was  spun  in  an  angle  centrifuge  for  15  minutes  at 
2,000 l~.p.~f.  The supernatant fluid only was retained  and was decanted into a 
100 cc. centrifuge flask and 5 cc. of 2 per cent aqueous solution of Mallinckrodt's 
tannic acid were added.  The mixture  was energetically  shaken  and then stored 
overnight in the cold.  Mter about 18 hours the material  was again shaken and 
centrifuged for 20 minutes  at 3,000 1~.1,.~.  The supernatant fluid was discarded 
and the precipitate washed,  with stirring,  in 50 cc. of Tyrode's solution.  After 
similar  centrifugation,  the sediment  was collected and resuspended  in 50 cc. of 
hormone broth, pH  =  7.6.  This suspension was stored in the cold and used as 
immunizing agent from 3 to 14 days after its preparation. 
The tannin-precipitated  virus  was injected  subcutal~eously in the amounts to 
be mentioned  and in several instances  produced locally  small, indurated masses 
which regressed after 1 or 2 weeks. 112 
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Results of Preventive Inoculations.--It will be seen from Table I  that 
of eight monkeys injected subcutaneously with the 5 per cent virus 
suspension  (M.  V.  and Philadelphia strains),  two died of non-polio- 
myelitis affections and of the remaining six,  two  became moribund 
after an attack of poliomyelitis following the first subcutaneous dose of 
2 cc.  In the one instance in which the antigen was Philadelphia virus, 
1 cc. inoculated intracranially induced poliomyelitis in a control mon- 
key.  When the immunizing agent was reduced in content of virus to 
1 per cent of cord by weight and only a  total of 4 cc. of it was given 
subcutaneously to each of four monkeys and 1 cc. intracerebrally to a 
fifth, none of the five so treated developed disease. 
The data in Table I  clearly show that material containing active 
virus can by itself give rise to fatal infection after a single subcutaneous 
injection.  It is  significant, however, that  of two monkeys receiving 
three such doses of the same virus sample, one failed to be protected 
against  a  subsequent  intracerebral  test  inoculation but  the  second 
resisted the intranasal test instillation.  Results based on the reactions 
of only two animals are inconclusive but they serve to bring out one 
of the difficulties met with in attempting to immunize animals with 
active virus preparations. 
The  power  of  the  various  tannin-precipitated  virus preparations 
to build up resistance was not great, for it is noted that of three mon- 
keys receiving the Philadelphia virus and which were given the intra- 
cerebral test inoculation, all developed poliomyelitis.  Of the treated 
animals injected with the 5 per cent antigen and tested intranasally 
for  immunity,  two  succumbed  and  one  monkey was  found  to  be 
resistant to  this and a  repeated test.  Of those receiving the  1 per 
cent material, both were resistant to the first intranasal test dose but 
were susceptible to a second test. 
Hence only one of the five animals receiving the immunizing agent 
was found resistant to the intranasal test and that one resisted both of 
two tests.  Even so, one cannot regard this monkey as immune, for, 
as Flexner (14) shows, monkeys can be refractory to several successive 
courses of instillations yet respond to a final one of the same virus.  In 
addition,  these results confirm Flexner's finding that  when virus is 
placed in contact with the nasal mucosa, pleocytosis may occur, but 
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associated  with  symptoms  of  infection  or  with  the  development of 
immunity. 
The capacity of tannin-precipitated virus to produce serum antiviral 
bodies is varied.  Of the series injected with 5 per cent virus antigen, 
the pooled serum of two monkeys and  individual  sera  of two others 
neutralized  virus by the method described; of the animals  given the 
1 per cent antigen,  the pooled serum of two neutralized  and that  of 
two others failed to do so.  To be noted is that in five instances treated 
monkeys yielded neutralizing  serum but were found, 51,  71, and 301 
days after  the last  immunizing  dose was given, to be susceptible in 
average degree to intracranial  or intranasal  contact with virus.  This 
is not unusual; it has recurred in the experiments soon to be described 
with formalin  and  ricinoleate.  Moreover,  Stewart  and  Rhoads  (1), 
Schultz and  Gebhardt  (15),  and  recently  Aycock  2 and  others  have 
reported the lack of correlation existing between serum antiviral bodies 
and immunity as tested by the cerebral or nasal routes.  In other words, 
the presence  in  the monkey of serum antiviral bodies, as produced by 
artificial  immunization  and  determined  by the described method,  is 
no definite indicator of the state of active resistance of the animal to 
the test doses used. 
To  summarize  the  results  of  preventive  treatment  with  tannin- 
precipitated poliomyelitis virus, it would appear that this product has 
failed as a  satisfactory immunizing  agent and that it is restricted by 
the same uncertainty  which living virus as such manifests  as a  pre- 
ventive  when  injected  under  similar  conditions.  Too  much  of  the 
material  can  induce  infection;  too  little,  inconstant  and  unreliable 
immunity. 
Active Ricinoleate-  Treated Virus as Immunizing Agent 
Kolmer (10), basing his experiments on those of McKinley and Larson  (16), 
employed 1 per cent sodium ricinoleate to attenuate but not inactivate the polio- 
myelitis virus in 4 per cent cord suspensions prepared from 1 month old glycer- 
olated tissue.  The ricinoleated material was kept in the cold for 1 month before 
use and then in one series of experiments 0.1 cc. of the agent per kilo body weight 
was injected subcutaneously five times at 5 day intervals into seven monkeys, and 
similar dosages were given intracutaneously  to three additional  animals.  They 
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showed no symptoms, and 1 month after the last treatment, when subjected to an 
intracerebral inoculation of 0.2 cc. of 5 per cent virus suspension,  one developed 
poliomyelitis and the others were unaffected.  The survivors were again injected 
intracerebrally with virus up to 17 months later and all but one survived a third 
cerebral test for resistance. 
In repeating  the  experiment with  sodium  ricinoleate-treated virus,  we used 
the same virus (M.V.  strain) which Kolmer employed and the sodium ricinoleate 
was sent us through the kindness of the same manufacturers)  The methods were 
those of Kolmer except as regards the intracerebral test dosage:  Kolmer employs 
as a  test dose for induced immunity unfiltered and we, filtered suspensions.  In 
addition,  we  employed nasal instillation,  as  described,  for this purpose,  a  pro- 
cedure which he omitted. 
Results  of Preventive  Inoculations  with Ricinoleate-Treated  Virus.- 
Reference  to  Table II shows  that  six monkeys  received  the  Kolmer 
vaccine.  Of two  tested  intracerebrally for immunity,  both  failed  to 
resist and of four instilled intranasally,  two developed the  disease on 
the first instillation and a  third on a  repeated test.  Thus only one of 
the  six animals resisted the tests for acquired  resistance. 
Table II reveals that the pooled serum of two treated animals and 
the  individual  sera  of  the  remaining  four  neutralized  virus  in  each 
instance.  Here  again,  as  occurred  with  tannin-precipitated  virus, 
the antiviral bodies, as determined by the method given, were present 
but  despite  this  fact  the  animals  succumbed  to  the  tests  for  active 
immunity. 
When these experiments were well advanced, a  paper was published 
by Schultz and Gebhardt (15), which stated:  "The serums of another 
series of animals 'immunized' earlier with living virus (Kolmer vaccine) 
neutralized  30 ~.  I. D. doses of virus per cubic centimeter,  but  when 
these  animals  were  subjected  to  intranasal  instillation  with  active 
virus, they all developed typical poliomyelitis."  We can thus confirm 
the findings of these  investigators. 
Formolized  Virus as Immunizing Agent 
In preparing materials, the methods of Brodie (9) were followed.  0.2 per cent 
formalin was added to 20 per cent active cord suspensions in equal volumes so 
that in the end 0.1 per cent formalin was in contact with 10 per cent virus suspen- 
sion.  This was kept at 37°C. for 16 hours, since at the time when this work was 
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done, Brodie stated that 12 to 16 hours of such contact served to inactivate polio- 
myelitis virus, and that the 16 hour material was employed by him as immunizing 
agent. 
With respect to dosage for immunization of monkeys, it was first stated by 
Brodie (17) that one dose of 5 cc. yielded as good results as two doses of 5 cc.; 
this was later (18) changed so that it was then declared that two injections  were 
more efficacious than a  single intradermal one of 5 cc.  In the following experi- 
ments, however,  two doses  of 5 cc. each were used throughout. 
The intracerebral test for induced resistance  as employed by Brodie was  made 
with  amounts  on  the  borderline of  infectivity, designated  as  "minimal  com- 
pletely paralyzing doses."  In Table III, the intracerebml test was the same as 
given in the foregoing series of experiments with tannin and sodium ricinoleate, 
so that a  proper comparison could be made of the different methods of immu- 
nization.  This consisted  of 0.2 cc. of filtered 5 per cent fresh cord suspensions. 
No mention is made by Brodie of determining immunity by means of intranasal 
instillation of virus; this we have carried out along with the intracerebral test. 
Results of Preventive Inoculation  with Formolized  Virus.--As will be 
seen in  Table III,  of eight monkeys injected with  formolized virus, 
only one resisted, and that one was found refractory to two successive 
intracranial  test  inoculations.  It  is  common  experience  among 
workers in this field to meet with an occasional monkey refractory to 
poliomyelitis virus, so that it is uncertain whether the animal in ques- 
tion was immunized by the formolized material or not. 
Of four sets of pooled serum, as indicated in Table III, one showed 
neutralization, another, none, and a  third and fourth so called incom- 
plete neutralization, due perhaps to low antibody content.  The lack 
of  correlation between  serum  antibodies  with  active protection has 
already been commented upon. 
It is therefore plain that this method offers, under the  experimental 
conditions employed, an ineffective immunizing material against polio- 
myelitis in monkeys. 
The experience of Schultz  and  Gebhardt  (15)  employing the same 
agent is as follows: 
They injected  fifteen  monkeys: three  subcutaneously, four  intramuscularly, 
and four  intradermaUy, giving  0.1 cc.  per  kilo  of  0.1 per cent formolized 10 per 
cent  virus,  and  four  intravenously  with  ten  times  this  amount,  five  times  at  weekly 
intervals.  24  days  after  the  last  immunizing  dose  the  animals received  three  ~.I.D. 
of virus.  "All developed the  disease  in  about  the same length of time,  and with 
about  as  extensive  paralysis  as  the  controls,  despite  the  fact  that  their  serums  sccm PETER  K.  OLITSKY  AND  HERALD  R.  COX  121 
to have acquired slight, but definite vinlcidal properties."  In additional experi- 
ments, Schultz and Gebhardt (15) injected the immunizing  agent repeatedly  in the 
brain of four monkeys and instilled it repeatedly in the  nasal cavities of four 
others.  All eight were proved susceptible  to later inoculation  with virus, in the 
brain in the first series and in the nose in the second. 
The results we have obtained are corroborative of those of Schultz 
and  Gebhardt,  although the latter  investigators employed a  lesser 
amount of vaccine, and lead to the conclusion that formolized virus 
is not an  effective preventive against poliomyelitis in  the monkey. 
Other earlier observers  (Abramson and Gerber,  19;  RSmer, 20; and 
Jungeblut and Engle, 21)  also did not succeed in inducing immunity 
by means of formolized poliomyelitis virus. 
DISCUSSION 
The object of this study was the investigation of the problem of 
active immunization of Macacus rhesus monkeys by means of chem- 
ically  treated  poliomyelitis  virus.  The  materials  employed  were 
tannin-precipitated virus and virus treated with sodium ricinoleate 
and with formalin.  The latter two substances are those with which 
the vaccines of Kolmer and Brodie respectively are prepared and the 
tannin  material  introduced  by  us  was  employed for  comparative 
observations. 
The virus of poliomyelitis treated with tannin or sodium ricinoleate 
retains its activity so that intracerebral inoculation of monkeys with 
the  preparations  induces  characteristic  experimental poliomyelitis. 
Indeed, Kolmer  (10)  records that 0.2  cc.  of his vaccine kept for S 
months  when  so  inoculated  induced  the  disease  within  12  days. 
Further, the tannin-precipitated virus itself brought on infection in 
two animals after a single subcutaneous injection of 2 cc.  It is there- 
fore plain that the chemical treatment in both instances did not act 
to attenuate the virus. 
The results of the experiments can be summarized by stating that 
if the immunizing agent contains a  sufficient amount of virus,  the 
danger arises of infecting an animal with the material itself.  Under 
the experimental conditions employed, these preparations, although 
active virus was present in them, failed to immunize the inoculated 
animals regularly.  Serum antiviral bodies were, however, produced 122  ACTIVE  IM-~UNIZATION  AGAINST  POLIOMYELITIS 
by means of the described methods but it was shown that animals in 
which these antibodies were present did not resist the ordinary tests 
for active immunity. 
From what is here reported, it is apparent that there is no advantage 
to be derived from the use of the tannin-precipitated, or ricinoleated 
virus as immunizing agents over unchanged active virus, as employed 
in  the past  in  this laboratory  (Flexner  and Lewis,  3;  Flexner  and 
Amoss, 22; Stewart and Rhoads,  1; and Rhoads, 23)  and elsewhere 
(Aycock and Kagan, 5, and others). 
A study of the recorded experiments of the past 25 years on immuni- 
zation of monkeys reveals that active poliomyelitis virus itself is not a 
potent antigen, as are some other viruses; uniform protection is rarely 
brought about through its use.  A  greater degree of success in  pro- 
tecting animals can, however, be achieved when large doses over long 
periods of time are employed--which fact might lead one to suppose 
that the difficulty with poliomyelitis virus as immunizing agent may 
be related simply to the amount of antigenic substance present.  Some 
viruses,  such as  those of equine encephalomyelitis (24)  and yellow 
fever* among several others, can be diluted to i0  -s and still be infective 
for the most susceptible host, whereas poliomyelitis virus can be di- 
luted to only a fraction of this amount to reach the limit of infectivity 
in the monkey.  It is still unknown why the antigenic capacity of this 
virus is relatively less than that of several others.  Finally, if amounts 
of virus  sufficing to  produce disease  in  some monkeys but  not  in 
others confer no immunity on the unaffected ones, it is to be expected 
that a lesser amount would be even less effective. 
We now come to an estimation of formolized  virus.  In this instance, 
the evidence of earlier observers (2), later of Brodie (9, 17), of Schultz 
and Gebhardt (15), and ourselves points to the inactivation of the virus 
by the chemical.  It is still an open question whether any form of 
inactive poliomyelitis virus retains the property of immunizing  animals 
(2).  An analysis of the results of the present investigation shows that 
active immunization with formolized virus by the Brodie method does 
not build up resistance in monkeys to the usual intracerebral or intra- 
nasal  tests for induced immunity.  The amount of antiviral bodies 
produced in the serum by this vaccine is slight and, as already indi- 
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cated,  the  treated  monkeys failed,  notwithstanding  the  presence of 
antibodies, to resist the tests for active immunity. 
There are, therefore, discrepancies in the conclusions of Brodie (9) 
and ourselves.  These may perhaps be ascribed to the fact that Brodie 
employs borderline dosages in his tests.  With such small doses, it is 
possible that  certain  monkeys may not receive what for them is an 
infective dose of virus.  At this point we wish to emphasize the fact 
that the intranasal  test dose for immunity employed here was within 
the range of a minimal infective dose, as we have pointed out before; 
nevertheless,  animals  receiving  formolized  virus  (or  tannin-precipi- 
tated or ricinoleated virus) and among them even those which possessed 
serum antiviral bodies were found to be susceptible to this test.  5 
There  remain  for  consideration  the  factors  derived  from  animal 
experimentation  which either  Kolmer or Brodie maintains as a basis 
for the claims that a  safe and  successful immunizing  agent has been 
made available for use in man. 
The first factor which Kolmer  (10)  stresses as the essential one is 
the  non-infectivity  of  his  preparation.  Kolmer  admits  that  the 
degree of attenuation by sodium ricinoleate is slight or of minor impor- 
tance but safety is acquired through the use of remote monkey passage 
virus that  has apparently lost its  infectivity for  man.  There  is  no 
experimental evidence for this assumption  (25, 26). 
The  second is that  ricinoleated  and formolized  vaccines  engender 
in monkeys serum antiviral bodies and that the same mechanism might 
apply in man.  It has been shown by Schultz and Gebhardt  (15) and 
5  As this article goes to press, Brodie states  (J. Am. Med.  Assn.,  1935, 105, 
1089) that  virus suspensions should be "just inactivated,  for overtreatment  or 
prolonged treatment  with solutions of formaldehyde reduced the antigenicity of 
the vaccine," and therefore recommends the use of virus inactivated  for 8 to 12 
hours instead of 16.  The distinction between "just inactivated"  and "overinac- 
tivation"  is not dear.  In view of the still more recent modification (18) of 5 to 6 
hours' contact with 0.1 per cent formalin at 37°C., it is apparent that this vaccine 
contains active virus as shown by Brodie in experiments in which 6 hours' treat- 
ment fails to inactivate the virus.  The amount of active material may be small 
since, as Brodie points out, monkeys develop the disease only after repeated inocu- 
lation  of 6 hour  treated  suspensions.  It  is known, however, that  such  small 
amounts of active virus do not induce protection in monkeys; still the possibility 
of infection during the period of immunization with an agent that contains active 
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by us that the antibody response in monkeys is slight, although the 
Kolmer vaccine  exceeded the  Brodie preparation  in  this  capacity. 
Despite the presence of acquired antiviral bodies in the serum no ac- 
tive resistance was developed to the recorded test doses for  induced 
immunity. 
Finally, the third factor relates to the active protection  conferred 
on monkeys by means of the  chemically treated virus.  Since  un- 
changed poliomyelitis virus lacks high antigenicity, it is to be expected 
that vaccines containing a lesser amount of active virus or virus that 
is inactivated would be still weaker in antigenic power.  The  results 
of the present experimental study reveal the ineffective and irregular 
immunizing capacity of these chemically treated viruses. 
CONCLUSION 
The results obtained in this investigation indicate that poliomyelitis 
virus treated with tannin,  sodium ricinoleate, or formalin does  not 
constitute a  satisfactory immunizing agent in monkeys against  the 
experimental disease. 
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